NEWS

Diversified pharmaceutical company with divisions
for novel medicines and complex generics

HOME NEWS News

ARBORMED News

[ AASLD The Liver Meeting® 2022 ] ArborMed Announces the therapeutic e…

페이지 정보

profile_image
작성자
댓글 0건 조회 6회 작성일 22-11-09 13:01

본문

ArborMed announced the therapeutic effects of the rare genetic disease Wilson's disease treatment "ARBM-101" at The Liver Meeting® 2022, the world's largest science conference in liver disease hosted by the American Association for the Study of Liver Disease (AASLD) from the 4th to the 8th of November 2022 (local time).

The American Liver Association is a world-class leading organization of scientists and health care professionals more than 10,000 researchers related to liver disease from around the world.

"Valentina Medici, a physician who has directly treated Wilson patients at UC Davis University and supervised a number of clinical trials for Wilson's treatment, and has been conducting mechanism research using Wilson's liver disease animal model for many years," ArborMed said.

ARBM-101 is being developed as an intravenous injection for patients with severe liver disease with Wilson's disease, and research results have been confirmed that it is effective in promoting rapid fecal discharge of copper while minimizing side effects based on very highly selective copper affinity in related animal models.

In the presentation of the AASLD The Liver Meeting® 2022, data were released confirming that when ARBM-101 was intravenously administered once a day for nine consecutive days, copper was discharged through feces from individuals whose abnormal signals were confirmed due to excessive accumulation of copper, and the liver level was maintained at a normal level for more than a month even after injection was stopped.

Arbormed previously announced the therapeutic effects of ARBM-101 on Wilson's disease animal model at the Wilson Aarhus 2022 Symposium, a Wilson's disease core group meeting in Denmark in May. Arbormed said, "We are drawing attention from liver experts at global conferences in the U.S. and Europe, and we are planning to develop it as therapeutic effects of ARBM-101 has been revealed and proven to be effective."
Wilson's disease is a rare disease that occurs in about 1 in every 30,000 people, with about 1,500 patients in Korea and about 10,000 patients in the United States, and the size of the treatment market in the United States is estimated to be about 3 trillion won.

댓글목록

등록된 댓글이 없습니다.